| Literature DB >> 30081496 |
Georges Herbein1,2.
Abstract
Besides its well-described impact in immunosuppressed patients, the role of human cytomegalovirus (HCMV) in the pathogenesis of cancer has been more recently investigated. In cancer, HCMV could favor the progression and the spread of the tumor, a paradigm named oncomodulation. Although oncomodulation could account for part of the protumoral effect of HCMV, it might not explain the whole impact of HCMV infection on the tumor and the tumoral microenvironment. On the contrary cases have been reported where HCMV infection slows down the progression and the spread of the tumor. In addition, HCMV proteins have oncogenic properties per se, HCMV activates pro-oncogenic pathways in infected cells, and recently the direct transformation of cells following HCMV infection has been described, which gave rise to tumors when injected in mice. Thus, beyond the oncomodulation model, this review will assess the direct transforming role of HMCV-infected cells and the potential classification of HCMV as an oncovirus.Entities:
Keywords: CTH cells; HCMV; cancer; oncomodulation; oncovirus
Mesh:
Year: 2018 PMID: 30081496 PMCID: PMC6115842 DOI: 10.3390/v10080408
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Figure 1The pros and cons of oncomodulation following human cytomegalovirus (HCMV) infection. NSG—NOD/SCID Gamma; NCAM-Neural Cell Adhesion Molecule.
Human cytomegalovirus (HCMV) products with oncogenic properties.
| HCMV Protein | Biological Effect | Oncogenic Feature |
|---|---|---|
| pUL123 (IE1) |
Entry into S phase Suppression of p53 and Rb activity Dysregulation of cyclin E expression Activation of telomerase Induction of IL-1 Inhibition of apoptosis Induction of chromosomal aberrations |
Cellular proliferation Evading growth suppressors Immortality Inflammation Enhanced cell survival Genome instability and mutation |
| pUL122 (IE2) |
Entry into S phase Binding to p53 Activation of PI3K/Akt pathway Induction of TGF-beta expression |
Cellular proliferation Evading growth suppressors Enhanced cell survival Increased immune suppression |
| pUS28 |
IL-6/JAK/STAT3 activation Activation of RhoA dependent mobility of U373 cells Induction of VEGF expression NF–kB activation |
Cellular proliferation Tumor growth Enhanced angiogenesis Enhanced cell survival |
| pUL111A (vIL10) |
STAT3 activation Production of homologs to immunosuppressive cytokines |
Cellular proliferation, migration and metastasis Telomerase activation Increased immune suppression |
| pUL76 |
Chromosomal breaks Induction of chromosomal aberrations |
Genome instability and mutation |
| pUL97 |
Phosphorylation and inactivation of pRb |
Evading growth suppressors |
| pUL82 (pp71) |
Rb downregulation Induction of E2F gene expression Increased mutation frequency |
Evading growth suppressors Cellular proliferation Genomic mutation |
| pUS2 |
Inhibition of the major histocompatility complex class I expression |
Escape of immune control |
| pUL16 |
Intracellular retention of NKG2D |
Escape of immune control |
| pUL83 (pp65) |
Increased mutation frequency Antagonizes the NKp30 activating receptor |
Genomic mutation Escape of immune control |
| pUL36 (vICA) |
Inhibits caspase-8 activation and apoptosis |
Enhanced cell survival |
| pUL37x1 (vMIA) |
Inhibits mitochondrial-mediated apoptosis |
Enhanced cell survival |
| lncRNA4.9 |
Viral latency, binding to PRC2 |
Cellular proliferation and transformation |
Figure 2Molecular pro-oncogenic pathways activated by HCMV products. HCMV proteins are in green, cellular effectors in black, and the hallmarks of cancer in red. Black small arrows describe up- or down-regulation of cytokines and cellular proteins.VEGF-Vascular endothelial growth factor; STAT3-Signal transducer and activator of transcription 3; PRC-Polycomb Repressive Complex.
Figure 3A model for HCMV oncogenesis: from viral proteins activating oncogenic pathways in infected HMECs to tumor growth in xenografted NOD/SCID Gamma (NSG) mice. CTH—CMV-transformed HMEC.